Title: 2025-2026 Regular Session HR 270 PN 2008 Bill Text (HTM)
Official Title: 
Number of Sections: 1
Source: versions - Printer's No. PN2008
Media Type: text/html

================================================================================

Section 1:
2025-2026 Regular Session HR 270 PN 2008 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 2008 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE RESOLUTION No.270 Session of 2025 INTRODUCED BY McANDREW, RIVERA, HOHENSTEIN, McNEILL, GIRAL, BRENNAN, HILL-EVANS, VENKAT, SANCHEZ, HADDOCK AND DONAHUE, JUNE 24, 2025 REFERRED TO COMMITTEE ON HEALTH, JUNE 24, 2025 A RESOLUTIONDesignating June 23, 2025, as "Dravet Syndrome Awareness Day" in Pennsylvania.WHEREAS, Dravet syndrome, formerly referred to as severe myoclonic epilepsy of infancy, is a genetic form of epilepsy that is characterized by temperature-sensitive seizures; andWHEREAS, These temperature-sensitive seizures, also referred to as febrile seizures, usually begin when an infant is between four months and twelve months of age and may manifest as grand mal seizures that involve convulsive movements of the entire body; andWHEREAS, Many infants with Dravet syndrome first experience a hemiclonic seizure where jerking movements only affect one side of the body, and the seizures are unlikely to stop on their own and can occur in clusters; andWHEREAS, After their first febrile seizure, the presence of a fever is unnecessary for another to occur, and future seizures could be triggered by any slight change in body temperature; and1234567891011121314151617 WHEREAS, Before the onset of these seizures, infants with Dravet syndrome reach their developmental milestones in time, but when seizures begin, the infants begin to exhibit developmental delays and features of autism spectrum disorder; andWHEREAS, In addition to seizures, patients with Dravet syndrome may experience severe intellectual and developmental disabilities, motor and speech impairments, behavioral difficulties and sleep abnormalities; andWHEREAS, Diagnosis of Dravet syndrome can be delayed and often requires expensive genetic testing because electroencephalogram and magnetic resonance imaging tests often produce normal results when seizures first appear; andWHEREAS, Genetic testing looks for a pathogenic variant in the SCN1A gene, which can impair the flow of sodium ions into brain neurons to lead to an overactivity of neurons that causes the seizures and epilepsy, but only 70% to 90% of children with Dravet syndrome have a mutated SCN1A gene, further complicating diagnosis; andWHEREAS, Dravet syndrome is treated by reducing or eliminating seizures through the use of anticonvulsant drugs and purified forms of cannabidiol that have been approved by the United States Food and Drug Administration, dietary therapy and vagus nerve stimulation in situations where medications are ineffective in controlling seizures; andWHEREAS, Treatment for Dravet syndrome is often also paired with family counseling and support, physical therapy, occupational therapy and speech therapy; andWHEREAS, Dravet syndrome is a rare condition, estimated to affect approximately 20,000 people in the United States, with 20250HR0270PN2008 - 2 - 123456789101112131415161718192021222324252627282930 only 1 in 16,000 babies being born with it; andWHEREAS, Patients with Dravet syndrome face a 15% to 20% mortality rate due to sudden unexpected death in epilepsy, prolonged seizures, seizure-related accidents and infections; andWHEREAS, The Dravet Syndrome Foundation has recognized the Epilepsy Neurogenetics Initiative at the Children's Hospital of Philadelphia, or CHOP, as a Dravet Comprehensive Care Center to acknowledge the expertise of CHOP providers in providing comprehensive care for children living with Dravet syndrome; andWHEREAS, Pennsylvania should take pride in having a Dravet Comprehensive Care Center in our State and in the hardworking physicians and medical professionals that have dedicated their lives and careers to helping children with this genetic neurological condition; andWHEREAS, "Dravet Syndrome Awareness Month" takes place each June in the United States, and "International Dravet Syndrome Awareness Day" is observed on June 23; andWHEREAS, The Dravet Syndrome Foundation recently recognized all those that have been lost to this condition on the fifth annual remembrance day that was held on June 15, 2025; therefore be itRESOLVED, That the House of Representatives designate June 23, 2025, as "Dravet Syndrome Awareness Day" in Pennsylvania.20250HR0270PN2008 - 3 - 123456789101112131415161718192021222324


================================================================================

Raw Text:
2025-2026 Regular Session HR 270 PN 2008 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 2008 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE RESOLUTION No.270 Session of 2025 INTRODUCED BY McANDREW, RIVERA, HOHENSTEIN, McNEILL, GIRAL, BRENNAN, HILL-EVANS, VENKAT, SANCHEZ, HADDOCK AND DONAHUE, JUNE 24, 2025 REFERRED TO COMMITTEE ON HEALTH, JUNE 24, 2025 A RESOLUTIONDesignating June 23, 2025, as "Dravet Syndrome Awareness Day" in Pennsylvania.WHEREAS, Dravet syndrome, formerly referred to as severe myoclonic epilepsy of infancy, is a genetic form of epilepsy that is characterized by temperature-sensitive seizures; andWHEREAS, These temperature-sensitive seizures, also referred to as febrile seizures, usually begin when an infant is between four months and twelve months of age and may manifest as grand mal seizures that involve convulsive movements of the entire body; andWHEREAS, Many infants with Dravet syndrome first experience a hemiclonic seizure where jerking movements only affect one side of the body, and the seizures are unlikely to stop on their own and can occur in clusters; andWHEREAS, After their first febrile seizure, the presence of a fever is unnecessary for another to occur, and future seizures could be triggered by any slight change in body temperature; and1234567891011121314151617 WHEREAS, Before the onset of these seizures, infants with Dravet syndrome reach their developmental milestones in time, but when seizures begin, the infants begin to exhibit developmental delays and features of autism spectrum disorder; andWHEREAS, In addition to seizures, patients with Dravet syndrome may experience severe intellectual and developmental disabilities, motor and speech impairments, behavioral difficulties and sleep abnormalities; andWHEREAS, Diagnosis of Dravet syndrome can be delayed and often requires expensive genetic testing because electroencephalogram and magnetic resonance imaging tests often produce normal results when seizures first appear; andWHEREAS, Genetic testing looks for a pathogenic variant in the SCN1A gene, which can impair the flow of sodium ions into brain neurons to lead to an overactivity of neurons that causes the seizures and epilepsy, but only 70% to 90% of children with Dravet syndrome have a mutated SCN1A gene, further complicating diagnosis; andWHEREAS, Dravet syndrome is treated by reducing or eliminating seizures through the use of anticonvulsant drugs and purified forms of cannabidiol that have been approved by the United States Food and Drug Administration, dietary therapy and vagus nerve stimulation in situations where medications are ineffective in controlling seizures; andWHEREAS, Treatment for Dravet syndrome is often also paired with family counseling and support, physical therapy, occupational therapy and speech therapy; andWHEREAS, Dravet syndrome is a rare condition, estimated to affect approximately 20,000 people in the United States, with 20250HR0270PN2008 - 2 - 123456789101112131415161718192021222324252627282930 only 1 in 16,000 babies being born with it; andWHEREAS, Patients with Dravet syndrome face a 15% to 20% mortality rate due to sudden unexpected death in epilepsy, prolonged seizures, seizure-related accidents and infections; andWHEREAS, The Dravet Syndrome Foundation has recognized the Epilepsy Neurogenetics Initiative at the Children's Hospital of Philadelphia, or CHOP, as a Dravet Comprehensive Care Center to acknowledge the expertise of CHOP providers in providing comprehensive care for children living with Dravet syndrome; andWHEREAS, Pennsylvania should take pride in having a Dravet Comprehensive Care Center in our State and in the hardworking physicians and medical professionals that have dedicated their lives and careers to helping children with this genetic neurological condition; andWHEREAS, "Dravet Syndrome Awareness Month" takes place each June in the United States, and "International Dravet Syndrome Awareness Day" is observed on June 23; andWHEREAS, The Dravet Syndrome Foundation recently recognized all those that have been lost to this condition on the fifth annual remembrance day that was held on June 15, 2025; therefore be itRESOLVED, That the House of Representatives designate June 23, 2025, as "Dravet Syndrome Awareness Day" in Pennsylvania.20250HR0270PN2008 - 3 - 123456789101112131415161718192021222324